Abstract:The commonly used host for industrial production of recombinant proteins Pichia pastoris, has been used in this work to produce the rabies virus glycoprotein (RABV-G). To allow a constitutive expression and the secretion of the expressed recombinant RABV-G, the PichiaPink™ commercialized expression vectors were modified to contain the constitutive GAP promoter and the α secretion signal sequences. Recombinant PichiaPink™ strains co-expressing the RABV-G and the protein chaperone PDI, have been then generated and screened for the best producer clone. The influence of seven carbon sources on the expression of the RABV-G, has been studied under different culture conditions in shake flask culture. An incubation temperature of 30°C under an agitation rate of 250 rpm in a filling volume of 10:1 flask/culture volume ratio were the optimal conditions for the RABV-G production in shake flask for all screened carbon sources. A bioreactor Fed batch culture has been then carried using glycerol and glucose as they were good carbon sources for cell growth and RABV-G production in shake flask scale. Cells were grown on glycerol during the batch phase then fed with glycerol or glucose defined solutions, a final RABV-G concentration of 2.7 µg/l was obtained with a specific product yield (YP/X) of 0.032 and 0.06 µg/g(DCW) respectively. The use of semi-defined feeding solution enhanced the production and the YP/X to 12.9 µg/l and 0.135 µg/g(DCW) respectively. However, the high cell density favored by these carbon sources resulted in oxygen limitation which influenced the glycosylation pattern of the secreted RABV-G. Alternatively, the use of sucrose as substrate for RABV-G production in large scale culture, resulted in less biomass production and a YP/X of 0.310 µg/g(DCW) was obtained. A cation exchange chromatography was then used for RABV-G purification as one step method. The purified protein was correctly folded and glycosylated and able to adopt trimeric conformation. The knowledges gained through this work offer a valuable insight into the bioprocess design of RABV-G production in Pichia pastoris to obtain a correctly folded protein which can be used during an immunization proposal for subunit Rabies vaccine development.

Analysis of the antigenic and immunogenic properties of the native rabies virus glycoprotein purified by Lens culinaris lectin affinity chromatography

Cell Surface Display of Rabies Virus Glycoprotein by Using Ice Nucleation Protein

Immunogenicity and Antigenicity of the Ectodomain of Rabies Virus Glycoprotein Stably Expressed in HEK293T Cells

[Expression and purification of rabies virus glycoprotein and analysis of its specific binding capacity to memory B cells]

Prokaryotic Expression,Purification and Identification of Rabies Virus Glycoprotein Extracellular Domain Gene

Production, purification, and characterization of recombinant rabies virus glycoprotein expressed in PichiaPink™ yeast

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Rabies Virus Glycoprotein Serology ELISA for Measurement of Neutralizing Antibodies in Sera of Vaccinated Human Subjects.

Efficient generation of monoclonal antibodies against major structural proteins of rabies virus with suckling mouse brain antigen.

Proteomic Profiling of Purified Rabies Virus Particles.

High-level Expression of Nucleoprotein Gene of Rabies Virus in Escherichia Coli

Analytical Methods for Evaluating the Immunogenicity of Recombinant Rabies Virus Glycoprotein Expressed in the Yeast Komagataella phaffii

Novel Strategy for Expression and Characterization of Rabies Virus Glycoprotein

[Competitive ELISA test system for the detection of antibodies to the rabies virus in animals (Rhabdoviridae: <I>Lyssavirus</I>)]

Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein

Rabies VLPs adjuvanted with saponin-based liposomes induce enhanced immunogenicity mediated by neutralizing antibodies in cattle, dogs and cats

Rapid fluorescent focus inhibition test optimization and validation: Improved detection of neutralizing antibodies to rabies virus

Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma

Predicting the presence and titer of rabies virus neutralizing antibodies from low-volume serum samples in low-containment facilities

Fine mapping and interaction analysis of a linear rabies virus neutralizing epitope.

Preparation and identification of monoclonal antibody specific to the V region of rabies virus G protein